Stock GE9 GENMAB A/S
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Genmab A/S BOERSE MUENCHEN

Equities

GE9

DK0010272202

Market Closed - BOERSE MUENCHEN
Other stock markets
 20:43:31 28/06/2024 BST 		5-day change 1st Jan Change
234.2 EUR -2.21% Intraday chart for Genmab A/S -3.94% -18.82%
06-28 Would you like some more inflation? Our Logo
06-28 Genmab, AbbVie's Lymphoma Therapy Recommended for Approval in EU MT

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Analyst opinion has improved significantly over the past four months.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • With a 2024 P/E ratio at 24.29 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
  • With an enterprise value anticipated at 4.29 times the sales for the current fiscal year, the company turns out to be overvalued.
  • The company appears highly valued given the size of its balance sheet.
  • The company is highly valued given the cash flows generated by its activity.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last few months, analysts have been revising downwards their earnings forecast.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
GENMAB A/S Stock Genmab A/S
-18.82% 15.91B -
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+15.20% 121B
B+
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+19.67% 113B
B+
ARGENX SE Stock argenx SE
+18.95% 26.02B
B
BIONTECH SE Stock BioNTech SE
-23.86% 19.39B
B+
BEIGENE, LTD. Stock BeiGene, Ltd.
-20.90% 15.09B
B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-46.14% 15.06B
A-
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+63.85% 14.93B
C+
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+4.49% 13.85B
C+
INSMED INCORPORATED Stock Insmed Incorporated
+116.20% 10.8B
C
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. GMAB Stock
  4. GE9 Stock
  5. Ratings Genmab A/S